By
Trending Posts
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being…
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…
Inside Medicare’s First Price Cuts: What a 38–79%…
A data-driven look at the first round of Medicare drug price negotiation, how it compares to the pricing…
Novartis’s U.S. Pricing Reckoning: How Generic Erosion and…
Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and what it signals…
Lilly’s U.S. Pricing Play: How Volume Economics Are…
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient access, and competitive…
With the Only FDA-Cleared Blood Test for Alzheimer’s…
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026 reflects a clear…
Can a $10 Billion Pipeline Opportunity Help Novartis…
Key Highlights A Landmark Quarter Reinforcing Confidence in Novartis’ Growth Trajectory Novartis’ second-quarter results send an encouraging signal…
Approved Two Months Early, Can GSK’s Jideytro Become…
Key Highlights A Landmark Approval Reflecting the Strength of GSK’s Oncology Push GSK’s announcement that the FDA has…
Can Insilico Medicine’s 9-Month AI Drug Discovery Record…
Key Highlights A Landmark Shift in How Fast New Medicines Can Reach Patients Insilico Medicine’s disclosure that it…
Can Novo Nordisk’s Lawsuit Against Eli Lilly Push…
Key Highlights A Landmark Legal Moment Reinforcing Standards in Patient-Facing Advertising Novo Nordisk’s decision to formally challenge Eli…
Trending Posts
Latest Stories
Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset
A quick-read guide to the Trump administration’s MFN pricing policy and what it means for…
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade
A data-driven look at the first round of Medicare drug price negotiation, how it compares…
Novartis’s U.S. Pricing Reckoning: How Generic Erosion and Growth-Brand Volume Are Reshaping the Post-Entresto Story
Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound and Mounjaro
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient…
Gallery
